Compare Incyte Corporation (INCY) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Southern Copper Corp — how do they compare? Incyte Corporation trades at $117.54 (market cap $23.11B), while Southern Copper Corp trades at $183.57 (market cap $146.07B). The key difference: Southern Copper Corp is far larger — about 6.3× Incyte Corporation's market cap, and Southern Copper Corp pays a 2.28% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SCCO | |
|---|---|---|
Market Cap | $23.11B | $146.07B |
Sector | Health | Basic Materials |
52-Week High | $118.52 | $218.85 |
52-Week Low | $67.38 | $90.54 |
Enterprise Value | $19.13B | $148.12B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Southern Copper (SCCO) trades at $175.27, up 1.62% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with revenue growth from $11.4B in 2024 to $13.4B in 2025 and net income rising to $4.3B. Valuation ratios are elevated with a P/E of 29.2 and P/B of 12.2. A recent dividend of $1.00 was declared, payable May 29, 2026, alongside a minor stock split.
Outlook is mixed: robust profitability and copper demand from AI infrastructure support growth, but high valuation and bearish analyst consensus pose risks. The consensus price target is $152.79, below the current price, indicating potential downside. Key risks include commodity price volatility and debt levels, though operational cash flow remains strong at $4.75B in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
